USPTO 2015–2025 USPTO PatentsView US Corporation

Gilead Sciences, Inc.

USPTO PatentsView assignee record - 561 granted patents across 18 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

561

Total patents granted

CPC technology areas

19.1

Avg claims per patent

+13%

5-year filing velocity

The verdict

Gilead holds 561 US patents across 18 technology areas, rank #817 of 50,000 tracked assignees.

#817
of 50,000 US assignees by volume: Top 5%
by Innovation Score (57.4/100): 19.1
avg claims per patent: +13%
filing velocity, last 5 yrs

Portfolio overview

Gilead Sciences, Inc. has been granted 561 US utility patents between 2015 and 2025, placing Gilead Sciences, Inc. at rank #817 across all assignees tracked by PlainPatent. This portfolio spans 18 distinct Cooperative Patent Classification (CPC) subclasses, averaging 19.1 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Gilead Sciences, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Gilead sits between Sekisui Chemical Co., Ltd. (565 patents, rank #813) and Valeo Vision (559 patents, rank #821) - the closest US assignees by grant volume. The composite Innovation Score of 57.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 298 grants, compared with 263 in the 2015–2019 window, a +13% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Gilead Sciences, Inc.'s 19.1 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 18 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Gilead Sciences, Inc. against peers pursuing similar technology classes.

Sekisui Chemical

565
Polaris Industries

563
Under Armour

563
Arts

561
Yaskawa Denki

561
Gilead Sciences ◀

561
TOTO

560
Unicharm

560
Valeo Vision

559

What this shows Gilead holds 561 patents at rank #817, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Gilead

By rank, the assignees closest to #817 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Gilead's primary technology class.

Gilead's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

57 Top 5% higher than 95% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Gilead Sciences, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	54	9.6%
2016	52	9.3%
2017	56	10.0%
2018	46	8.2%
2019	55	9.8%
2020	37	6.6%
2021	41	7.3%
2022	42	7.5%
2023	65	11.6%
2024	74	13.2%
2025	39	7.0%

Which technologies does Gilead Sciences, Inc. patent most?

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 492

C07D - HETEROCYCLIC COMPOUNDS 413

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 358

C07F - ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM 86

Y02A - TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE 72

C07B - GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR 56

C07C - ACYCLIC OR CARBOCYCLIC COMPOUNDS 54

C07H - SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 53

C07K - PEPTIDES 52

Y02P - CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS 12

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 12

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 10

A61M - DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR 4

C12Y - ENZYMES 4

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 3

Top 15 of 18 technology areas

Patent Moat Analysis

Portfolio Volume Moderate

Tech Breadth Focused

Claim Depth Standard

Velocity Growing

Where it ranks

Overall rank by patents

#817

Across all tracked assignees

Innovation Score

57.4 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Gilead Sciences, Inc. hold?

Gilead Sciences, Inc. holds 561 US granted patents filed between 2015 and 2025, spanning 18 technology areas.

What is Gilead Sciences, Inc.'s Innovation Score?

Gilead Sciences, Inc. has an Innovation Score of 57.4 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Gilead Sciences, Inc. focus on?

Gilead Sciences, Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 492 patents. The company has filed patents in 18 CPC subclasses total.

Is Gilead Sciences, Inc.'s patent filing rate increasing or decreasing?

Gilead Sciences, Inc.'s recent filing velocity is +13% compared to the prior five-year period. The company is maintaining or growing its patent output.

What does claim depth mean for Gilead Sciences, Inc.'s patents?

Gilead Sciences, Inc.'s patents average 19.1 claims each. This falls within the standard range, providing solid legal coverage.

How is the Gilead Sciences, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Gilead's 561 grants land it in the top 5% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Gilead ranks #817 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.